UroToday1d
ASCO GU 2023: ZIRCON: Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma
(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 ...
UroToday1d
EAU 2023: 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma - Results from Phase 3 ZIRCON Study
(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10 th and 13 th, 2023 was host to a game changing session. Professor Peter Mulders ...
UroToday1d
ASCO 2024: Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between May 31 and June 4 was host to the Rapid Oral Abstract Session: Genitourinary Cancer - ...
UroToday1d
SUO 2024: Implementing Smoking Cessation in the Urologic Oncology Setting
(UroToday.com) The 2024 SUO annual meeting included a session on smoking cessation, vaping, and e-cigarettes, featuring a presentation by Dr. Richard Matulewicz discussing implementing smoking ...
UroToday1d
SUO 2024: Heterogeneity of Intermediate Risk NMIBC
(UroToday.com) The 2024 SUO annual meeting included a session on non muscle invasive bladder cancer (NMIBC), featuring a presentation by Dr. Sima Porten discussing the heterogeneity of intermediate ...
UroToday2d
SUO 2024: Adjuvant Radiation Following Cystectomy: Underutilized Therapy?
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Omar Mian discussed the role of adjuvant ...
UroToday4d
Bipolar Androgen Therapy: Rationale, Candidate Patients, and Latest Evidence for mCRPC Patients
Androgen receptor inhibition remains the mainstay treatment of advanced prostate cancer. However, therapeutic resistance to androgen receptor inhibition is almost universal. Prostate cancer cells can ...
UroToday5d
Antibiotic therapy for treating overactive bladder is not supported by clinical evidence.
A number of reports have suggested that the use of prolonged antibiotic treatment could be an effective therapy for patients with overactive bladder (OAB); however, this approach is contrary to ...
UroToday5d
Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials.
Neoadjuvant cisplatin-based chemotherapy followed by radical surgery is the standard treatment for muscle-invasive urothelial carcinoma (MIUC). The Checkmate-274 and AMBASSADOR trials have ...
UroToday5d
Risk factors, urodynamic characteristics, and distress associated with nocturnal enuresis in overactive bladder -wet women.
Patients with overactive bladder syndrome-wet (OAB-wet) experience urgency urinary incontinence, particularly urinary frequency and nocturia. Nocturnal enuresis (NE) is less addressed among OAB-wet ...
UroToday5d
The Association Between Anthropometric Indices and Overactive Bladder (OAB): A Cross-Sectional Study From the NHANES 2005-2018.
The association between different anthropometric indices, including body mass index (BMI), a body shape index (ABSI), lipid accumulation product (LAP), visceral adiposity index (VAI), waist ...
UroToday5d
Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy - Beyond the Abstract
Advances in imaging interpretation have led to more accurate risk stratification for men being diagnosed with prostate cancer (PCa). A significant number of men are diagnosed with low-risk prostate ...